“Advancements in Targeted Therapies and Neuroimaging Technologies”
- One prominent trend in the global infantile spasms therapeutics market is the advancement of targeted therapies and the integration of sophisticated neuroimaging technologies
- These innovations support earlier and more accurate diagnosis, while enabling the development of treatments that address specific underlying neurological abnormalities or genetic mutations
- For instance, the use of advanced MRI and PET scans allows clinicians to pinpoint structural brain abnormalities linked to spasms, aiding in the selection of the most effective, personalized treatment plans
- Targeted drug development, including therapies focused on the mTOR and GABA pathways, is gaining momentum, improving outcomes with fewer side effects
- This trend is transforming the management of infantile spasms by enabling precision medicine approaches, enhancing treatment efficacy, and supporting better long-term developmental outcomes for affected infants
